{"component": "clause", "props": {"groups": [{"snippet": "If a Third Party sues a Party (the \u201cSued Party\u201d) alleging that the Sued Party\u2019s or the Sued Party\u2019s Sublicensees\u2019 Development, Manufacture or Commercialization of the Collaboration Compound or Collaboration Product infringes or shall infringe said Third Party\u2019s Patent Right(s) or misappropriates said Third Party\u2019s trade secret, [**] to defend or settle such claim in its own name after consultation with \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 and in connection with its defense of any such Third Party suit, \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 shall provide reasonable assistance to AstraZeneca for such defense and shall join such suit if deemed a necessary party. AstraZeneca shall keep \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587, if \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 has not joined in such suit, reasonably informed on a quarterly basis, in person or by telephone, prior to and during the pendency of any such suit. AstraZeneca shall not admit the invalidity of any patent within the \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 Patent Rights, the AstraZeneca Patent Rights or the Joint Patent Rights, nor settle any such suit, without written consent of the other Party, such consent not to be unreasonably withheld or delayed. Subject to \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2019\u2587 indemnity obligations pursuant to Section 11.1, all litigation expenses, including settlement costs, royalties paid in settlement of any such suit, and the payment of any damages to the Third Party will be paid by AstraZeneca.", "snippet_links": [{"key": "a-third-party", "type": "clause", "offset": [3, 16]}, {"key": "a-party", "type": "clause", "offset": [22, 29]}, {"key": "sued-party", "type": "definition", "offset": [36, 46]}, {"key": "collaboration-compound", "type": "definition", "offset": [167, 189]}, {"key": "collaboration-product", "type": "definition", "offset": [193, 214]}, {"key": "trade-secret", "type": "definition", "offset": [316, 328]}, {"key": "after-consultation-with", "type": "clause", "offset": [382, 405]}, {"key": "in-connection-with", "type": "clause", "offset": [420, 438]}, {"key": "assistance-to", "type": "clause", "offset": [516, 529]}, {"key": "necessary-party", "type": "definition", "offset": [596, 611]}, {"key": "on-a-quarterly-basis", "type": "definition", "offset": [709, 729]}, {"key": "in-person", "type": "clause", "offset": [731, 740]}, {"key": "by-telephone", "type": "definition", "offset": [744, 756]}, {"key": "prior-to", "type": "definition", "offset": [758, 766]}, {"key": "the-\u2587", "type": "clause", "offset": [873, 878]}, {"key": "astrazeneca-patent-rights", "type": "clause", "offset": [906, 931]}, {"key": "joint-patent-rights", "type": "definition", "offset": [939, 958]}, {"key": "consent-of-the", "type": "clause", "offset": [1002, 1016]}, {"key": "other-party", "type": "definition", "offset": [1017, 1028]}, {"key": "consent-not-to-be-unreasonably-withheld", "type": "clause", "offset": [1035, 1074]}, {"key": "subject-to", "type": "definition", "offset": [1087, 1097]}, {"key": "indemnity-obligations", "type": "definition", "offset": [1110, 1131]}, {"key": "section-111", "type": "clause", "offset": [1144, 1156]}, {"key": "litigation-expenses", "type": "definition", "offset": [1162, 1181]}, {"key": "settlement-costs", "type": "definition", "offset": [1193, 1209]}, {"key": "settlement-of", "type": "clause", "offset": [1229, 1242]}, {"key": "payment-of", "type": "definition", "offset": [1266, 1276]}, {"key": "the-third-party", "type": "definition", "offset": [1292, 1307]}], "size": 10, "samples": [{"hash": "3HZuJywoEnL", "uri": "/contracts/3HZuJywoEnL#third-party-suit", "label": "License and Collaboration Agreement (Hutchison China MediTech LTD)", "score": 32.1704312115, "published": true}, {"hash": "g5TYfTvULRw", "uri": "/contracts/g5TYfTvULRw#third-party-suit", "label": "License and Collaboration Agreement (Hutchison China MediTech LTD)", "score": 30.4072553046, "published": true}, {"hash": "idtJNVrIV8W", "uri": "/contracts/idtJNVrIV8W#third-party-suit", "label": "License and Collaboration Agreement (Hutchison China MediTech LTD)", "score": 30.3305954825, "published": true}], "hash": "8b39400b4d9c51a679f06dfb34df712e", "id": 1}, {"snippet": "If a Third Party sues a Party (the \u201cSued Party\u201d) alleging that the Sued Party\u2019s or the Sued Party\u2019s Affiliates\u2019 or Sublicensees\u2019, Development, Manufacture or Commercialization of the Licensed Compound or the Product infringes or will infringe said Third Party\u2019s patent right(s) or misappropriates said Third Party\u2019s trade secret, then upon the Sued Party\u2019s request and in connection with the Sued Party\u2019s defense of any such Third Party suit, the other Party will provide reasonable assistance to the Sued Party for such defense and will join such suit if deemed a necessary party. The Sued Party will keep the other Party, if such other Party has not joined in such suit, reasonably informed on a quarterly basis, in person or by telephone, prior to and during the pendency of any such suit. The Sued Party will not admit the invalidity of any Patent Right licensed to a Party hereunder, nor settle any such suit, without written consent of the other Party, such consent not to be unreasonably withheld. Subject to the Parties\u2019 respective indemnity obligations pursuant to Section 9.1 and 9.2, and without limiting anything in Section 4.3.4, all litigation expenses, including settlement costs, royalties paid in settlement of any such suit, and the [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. payment of any damages to the Third Party, will be paid by the Sued Party. Notwithstanding the foregoing, if the Sued Party seeks an indemnification pursuant to Section 9.1 or Section 9.2, then the provisions of such Section 9.1 or Section 9.2, and the provisions of Section 9.3 will apply and will control and will supersede this Section 7.7.2. to the extent it is inconsistent with Section 9.1, Section 9.2, or Section 9.3.", "snippet_links": [{"key": "a-third-party", "type": "clause", "offset": [3, 16]}, {"key": "a-party", "type": "clause", "offset": [22, 29]}, {"key": "sued-party", "type": "definition", "offset": [36, 46]}, {"key": "licensed-compound", "type": "definition", "offset": [183, 200]}, {"key": "the-product", "type": "clause", "offset": [204, 215]}, {"key": "patent-right", "type": "clause", "offset": [262, 274]}, {"key": "trade-secret", "type": "definition", "offset": [316, 328]}, {"key": "in-connection-with", "type": "clause", "offset": [369, 387]}, {"key": "other-party", "type": "definition", "offset": [447, 458]}, {"key": "will-provide", "type": "clause", "offset": [459, 471]}, {"key": "assistance-to-the", "type": "clause", "offset": [483, 500]}, {"key": "necessary-party", "type": "definition", "offset": [565, 580]}, {"key": "on-a-quarterly-basis", "type": "definition", "offset": [693, 713]}, {"key": "in-person", "type": "clause", "offset": [715, 724]}, {"key": "by-telephone", "type": "definition", "offset": [728, 740]}, {"key": "prior-to", "type": "definition", "offset": [742, 750]}, {"key": "consent-of-the", "type": "clause", "offset": [931, 945]}, {"key": "consent-not-to-be-unreasonably-withheld", "type": "clause", "offset": [964, 1003]}, {"key": "the-parties", "type": "definition", "offset": [1016, 1027]}, {"key": "indemnity-obligations", "type": "definition", "offset": [1040, 1061]}, {"key": "section-91", "type": "definition", "offset": [1074, 1085]}, {"key": "without-limiting", "type": "definition", "offset": [1099, 1115]}, {"key": "litigation-expenses", "type": "definition", "offset": [1147, 1166]}, {"key": "settlement-costs", "type": "definition", "offset": [1178, 1194]}, {"key": "settlement-of", "type": "clause", "offset": [1214, 1227]}, {"key": "this-exhibit", "type": "definition", "offset": [1270, 1282]}, {"key": "pursuant-to-a", "type": "definition", "offset": [1301, 1314]}, {"key": "confidential-treatment-request", "type": "clause", "offset": [1315, 1345]}, {"key": "the-commission", "type": "clause", "offset": [1416, 1430]}, {"key": "payment-of", "type": "definition", "offset": [1432, 1442]}, {"key": "the-third-party", "type": "definition", "offset": [1458, 1473]}, {"key": "notwithstanding-the-foregoing", "type": "clause", "offset": [1507, 1536]}, {"key": "section-92", "type": "clause", "offset": [1608, 1619]}, {"key": "section-93", "type": "clause", "offset": [1699, 1710]}, {"key": "section-772", "type": "clause", "offset": [1763, 1776]}, {"key": "to-the-extent", "type": "clause", "offset": [1778, 1791]}], "size": 7, "samples": [{"hash": "4F45aJSmFzJ", "uri": "/contracts/4F45aJSmFzJ#third-party-suit", "label": "License Agreement", "score": 23.932238193, "published": true}, {"hash": "5dzKfrgQyH3", "uri": "/contracts/5dzKfrgQyH3#third-party-suit", "label": "License Agreement (Ironwood Pharmaceuticals Inc)", "score": 21.0876112252, "published": true}], "hash": "19eb566b6e10310437bba7eda0971e11", "id": 2}, {"snippet": "If a Third Party sues a Party (the \u201cSued Party\u201d) alleging that the Sued Party\u2019s or the Sued Party\u2019s Sublicensees\u2019 Development, Manufacture or Commercialization of HMPL-004 or the Product infringes or will infringe said Third Party\u2019s Patent Right(s) or misappropriates said Third Party\u2019s trade secret or has otherwise resulted in a claim in respect of product liability arising from or relating to HMPL-004 or a Product, then at Nestl\u00e9\u2019s option, the Company will defend or settle such claim in its own name after consultation with Nestl\u00e9 and in connection with its defense of any such Third Party suit, Nestl\u00e9 will provide reasonable assistance to the Company for such defense and will join such suit if deemed a necessary party. The Company will keep Nestl\u00e9 reasonably informed, in person or by telephone, prior to and during the pendency of any such suit, where Nestl\u00e9 has not joined in such suit the information will be provided at minimum on a monthly basis. Where the Company will defend such claim, the Company will have full control of such litigation or steps but will not, without the prior written consent of Nestl\u00e9, such consent not to be unreasonably withheld, enter into any compromise or settlement relating to such litigation, including without limitation that (a) admits the invalidity or unenforceability of any Company Patent Right or any other Patent Right of Nestl\u00e9 or its Affiliates or (b) requires the Company to abandon any Company Patent Right or requires Nestl\u00e9 or its Affiliates to abandon any other Patent Right of Nestl\u00e9 or its Affiliates (c) admits to any defect in HMPL\u00ac004 or a Product which has, or could have contributed to, a product liability claim. Nestl\u00e9 will, at its own expense, cooperate with the Company in any such litigation. Nestl\u00e9 may however elect to defend or settle such claim on behalf of the Company in which case Nestl\u00e9 will have full control of such litigation or steps and will defend or settle such claim in its own name and/or on behalf of the Company after consultation with the Company and in connection with its defense of any such Third Party suit, the Company will provide reasonable assistance to Nestl\u00e9 for such defense and will join such suit if deemed a necessary party. Nestl\u00e9 will keep the Company reasonably informed, in person or by telephone, prior to and during the pendency of any such suit, where the Company has not joined in such suit the information will be provided at minimum on a monthly basis. Where Nestl\u00e9 will defend such claim, Nestl\u00e9 will have full control of such litigation or steps but will not, without the prior written consent of the Company, such consent not to be unreasonably withheld, enter into any compromise or settlement relating to such litigation, including without limitation that (a) admits the invalidity or unenforceability of any Company Patent Right or (b) requires the Company to abandon any Company Patent Right (c) admits to any defect in HMPL-004 or a Product which has, or could have contributed to, a product liability claim. The Company will, at its own expense, cooperate with Nestl\u00e9 in any such litigation.", "snippet_links": [{"key": "a-third-party", "type": "clause", "offset": [3, 16]}, {"key": "a-party", "type": "clause", "offset": [22, 29]}, {"key": "sued-party", "type": "definition", "offset": [36, 46]}, {"key": "the-product", "type": "clause", "offset": [175, 186]}, {"key": "patent-right", "type": "clause", "offset": [233, 245]}, {"key": "trade-secret", "type": "definition", "offset": [287, 299]}, {"key": "in-respect-of", "type": "clause", "offset": [337, 350]}, {"key": "relating-to", "type": "definition", "offset": [385, 396]}, {"key": "after-consultation-with", "type": "clause", "offset": [506, 529]}, {"key": "in-connection-with", "type": "clause", "offset": [541, 559]}, {"key": "assistance-to-the-company", "type": "clause", "offset": [633, 658]}, {"key": "necessary-party", "type": "definition", "offset": [712, 727]}, {"key": "in-person", "type": "clause", "offset": [779, 788]}, {"key": "by-telephone", "type": "definition", "offset": [792, 804]}, {"key": "prior-to", "type": "definition", "offset": [806, 814]}, {"key": "the-information", "type": "clause", "offset": [898, 913]}, {"key": "monthly-basis", "type": "definition", "offset": [947, 960]}, {"key": "where-the-company", "type": "clause", "offset": [962, 979]}, {"key": "control-of", "type": "definition", "offset": [1031, 1041]}, {"key": "prior-written-consent", "type": "clause", "offset": [1093, 1114]}, {"key": "consent-not-to-be-unreasonably-withheld", "type": "clause", "offset": [1131, 1170]}, {"key": "compromise-or-settlement", "type": "clause", "offset": [1187, 1211]}, {"key": "including-without-limitation", "type": "clause", "offset": [1241, 1269]}, {"key": "invalidity-or-unenforceability", "type": "clause", "offset": [1290, 1320]}, {"key": "company-patent", "type": "definition", "offset": [1328, 1342]}, {"key": "right-of", "type": "definition", "offset": [1369, 1377]}, {"key": "product-liability-claim", "type": "clause", "offset": [1659, 1682]}, {"key": "cooperate-with", "type": "clause", "offset": [1717, 1731]}, {"key": "company-in", "type": "clause", "offset": [1736, 1746]}, {"key": "behalf-of-the-company", "type": "clause", "offset": [1827, 1848]}, {"key": "the-company-will-provide", "type": "clause", "offset": [2107, 2131]}, {"key": "the-company-has", "type": "definition", "offset": [2368, 2383]}, {"key": "consent-of-the-company", "type": "clause", "offset": [2607, 2629]}], "size": 6, "samples": [{"hash": "4bweqQ7whYR", "uri": "/contracts/4bweqQ7whYR#third-party-suit", "label": "Joint Venture Agreement (Hutchison China MediTech LTD)", "score": 30.4072553046, "published": true}, {"hash": "9GT7KCnQ9ta", "uri": "/contracts/9GT7KCnQ9ta#third-party-suit", "label": "Joint Venture Agreement (Hutchison China MediTech LTD)", "score": 30.3305954825, "published": true}], "hash": "db906889f26ac4f5eb1025c8f5430699", "id": 3}, {"snippet": "If a Third Party sues Licensee alleging that the Development, Manufacture or Commercialization of any Licensed Asset or any Product in the Field in the Licensed Territory by Licensee or its Sublicensees infringes or misappropriates said Third Party\u2019s Intellectual Property, then, as between the Parties, [***].", "snippet_links": [{"key": "a-third-party", "type": "clause", "offset": [3, 16]}, {"key": "the-development", "type": "clause", "offset": [45, 60]}, {"key": "licensed-asset", "type": "definition", "offset": [102, 116]}, {"key": "in-the-field", "type": "clause", "offset": [132, 144]}, {"key": "licensed-territory", "type": "clause", "offset": [152, 170]}, {"key": "by-licensee", "type": "clause", "offset": [171, 182]}, {"key": "intellectual-property", "type": "definition", "offset": [251, 272]}, {"key": "between-the-parties", "type": "clause", "offset": [283, 302]}], "size": 5, "samples": [{"hash": "ep05kbNgvtr", "uri": "/contracts/ep05kbNgvtr#third-party-suit", "label": "License Agreement (Zenas BioPharma, Inc.)", "score": 35.6392881588, "published": true}, {"hash": "kIP1mSoKnFd", "uri": "/contracts/kIP1mSoKnFd#third-party-suit", "label": "License Agreement (Zenas BioPharma, Inc.)", "score": 35.0643394935, "published": true}, {"hash": "jo9C3IooZx4", "uri": "/contracts/jo9C3IooZx4#third-party-suit", "label": "License Agreement (Zenas BioPharma, Inc.)", "score": 35.0643394935, "published": true}], "hash": "bc6011c901985cdaad560d216e0d505d", "id": 4}, {"snippet": "If a Third Party sues a Party (the \u201cSued Party\u201d) alleging that the development, manufacture or commercialization of any Product by the Sued Party or its Affiliate, Licensee or Sublicensee infringes or shall infringe said Third Party\u2019s Patent Right(s) or misappropriates said Third Party\u2019s trade secret, then upon the Sued Party\u2019s request and in connection with the Sued Party\u2019s defense of any such Third Party suit, the other Party shall provide reasonable assistance to the Sued Party for such defense and shall join such suit if deemed a necessary party. The Sued Party shall keep the other Party, if such other Party has not joined in such suit, reasonably informed on a quarterly basis, in person or by telephone, prior to and during the pendency of any such suit. The Sued Party shall not admit the invalidity of any patent within the Egalet Patent Rights or the Shionogi Patent Rights, nor settle any such suit, without the prior written consent of the other Party, such consent not to be unreasonably withheld. Subject to the Parties\u2019 respective indemnity obligations pursuant to Section 11.1 and 11.2, all litigation expenses, including settlement costs, royalties paid in settlement of any such suit, and the payment of any damages to the Third Party will be paid by the Sued Party.", "snippet_links": [{"key": "a-third-party", "type": "clause", "offset": [3, 16]}, {"key": "a-party", "type": "clause", "offset": [22, 29]}, {"key": "sued-party", "type": "definition", "offset": [36, 46]}, {"key": "the-development", "type": "clause", "offset": [63, 78]}, {"key": "trade-secret", "type": "definition", "offset": [289, 301]}, {"key": "in-connection-with", "type": "clause", "offset": [342, 360]}, {"key": "other-party", "type": "definition", "offset": [420, 431]}, {"key": "assistance-to-the", "type": "clause", "offset": [457, 474]}, {"key": "necessary-party", "type": "definition", "offset": [540, 555]}, {"key": "on-a-quarterly-basis", "type": "definition", "offset": [669, 689]}, {"key": "in-person", "type": "clause", "offset": [691, 700]}, {"key": "by-telephone", "type": "definition", "offset": [704, 716]}, {"key": "prior-to", "type": "definition", "offset": [718, 726]}, {"key": "patent-rights", "type": "definition", "offset": [847, 860]}, {"key": "consent-of-the", "type": "clause", "offset": [944, 958]}, {"key": "consent-not-to-be-unreasonably-withheld", "type": "clause", "offset": [977, 1016]}, {"key": "the-parties", "type": "definition", "offset": [1029, 1040]}, {"key": "indemnity-obligations", "type": "definition", "offset": [1053, 1074]}, {"key": "section-111", "type": "clause", "offset": [1087, 1099]}, {"key": "litigation-expenses", "type": "definition", "offset": [1114, 1133]}, {"key": "settlement-costs", "type": "definition", "offset": [1145, 1161]}, {"key": "settlement-of", "type": "clause", "offset": [1181, 1194]}, {"key": "payment-of", "type": "definition", "offset": [1218, 1228]}, {"key": "the-third-party", "type": "definition", "offset": [1244, 1259]}], "size": 3, "samples": [{"hash": "lryT2BOxBX0", "uri": "/contracts/lryT2BOxBX0#third-party-suit", "label": "Development and Licensing Agreement", "score": 27.0424366872, "published": true}, {"hash": "joAnwxXep4O", "uri": "/contracts/joAnwxXep4O#third-party-suit", "label": "Collaboration and License Agreement (Egalet Corp)", "score": 24.923340178, "published": true}], "hash": "27bdb028401aa2e372b8f81337aee582", "id": 5}, {"snippet": "Subject to Article 13 (Indemnification), in the event of any threatened or actual suit against the Company in consequence of the exercise of any rights and licenses granted herein, the Company shall; promptly inform Canada and the Parties will Jointly decide on the steps to be taken in the circumstances. In any event, the Company will always have the sole right to defend itself as it determines against any suit or other action brought against the Company or its employees or agents.", "snippet_links": [{"key": "article-13", "type": "clause", "offset": [11, 21]}, {"key": "in-the-event-of", "type": "definition", "offset": [41, 56]}, {"key": "company-in", "type": "clause", "offset": [99, 109]}, {"key": "exercise-of", "type": "clause", "offset": [129, 140]}, {"key": "licenses-granted", "type": "clause", "offset": [156, 172]}, {"key": "the-company-shall", "type": "clause", "offset": [181, 198]}, {"key": "the-parties-will", "type": "clause", "offset": [227, 243]}, {"key": "the-company-will", "type": "clause", "offset": [320, 336]}, {"key": "right-to-defend", "type": "clause", "offset": [358, 373]}, {"key": "suit-or-other-action", "type": "clause", "offset": [410, 430]}], "size": 3, "samples": [{"hash": "ioshOfKTNPq", "uri": "/contracts/ioshOfKTNPq#third-party-suit", "label": "Technology Contracts (Newlink Genetics Corp)", "score": 22.7549623546, "published": true}, {"hash": "iYohF2ti15F", "uri": "/contracts/iYohF2ti15F#third-party-suit", "label": "License Agreement (Newlink Genetics Corp)", "score": 21.9691991786, "published": true}], "hash": "23aff285487a61ac28a0537124e43229", "id": 6}, {"snippet": "In the event that a third party institutes a suit against Company for infringement, Company will promptly inform CHMC and keep CHMC regularly informed of the proceedings. In the event that such third party institutes a suit against CHMC or CHMC is joined as a party, CHMC will have the right to control the defense of the suit.", "snippet_links": [{"key": "in-the-event", "type": "clause", "offset": [0, 12]}, {"key": "a-third-party", "type": "clause", "offset": [18, 31]}, {"key": "for-infringement", "type": "clause", "offset": [66, 82]}, {"key": "company-will", "type": "clause", "offset": [84, 96]}, {"key": "the-proceedings", "type": "clause", "offset": [154, 169]}, {"key": "a-party", "type": "clause", "offset": [258, 265]}, {"key": "right-to-control", "type": "clause", "offset": [286, 302]}], "size": 2, "samples": [{"hash": "5vWep2XbwLg", "uri": "/contracts/5vWep2XbwLg#third-party-suit", "label": "Exclusive License Agreement (Blue Water Vaccines Inc.)", "score": 32.909650924, "published": true}, {"hash": "9cY1uUU17p1", "uri": "/contracts/9cY1uUU17p1#third-party-suit", "label": "Exclusive License Agreement (Blue Water Vaccines Inc.)", "score": 32.8439425051, "published": true}], "hash": "5652edcfd8e99539313838795d10b50f", "id": 7}, {"snippet": "If Biosource is sued for patent infringement of any Third Party patents and such infringement arises out of the development, manufacture, use, offer for sale, sale or importation of Biosource Products, where Biosource is paying royalties to TDCC for such Products under this Agreement and where such infringement arises solely and directly from the use of Production Technology Owned by DAS or Product Technology Owned by TDCC licensed to Biosource hereunder, the parties shall promptly meet to discuss the course of action to be taken to resolve or defend any such infringement litigation. In such event, Biosource shall determine the course of action with regard to such infringement litigation in its sole discretion, and TDCC and/or DAS, as appropriate, shall provide Biosource with such assistance as is reasonably necessary and shall cooperate in the defense of any such action. In the event that there is a settlement to the litigation or Biosource takes a license to the Third Party technology, TDCC and Biosource shall re-negotiate the royalty payments in Article 6 to in light of any additional royalties or costs that Biosource may have incurred in obtaining freedom to operate for the Production Technology Owned by DAS or Product Technology Owned by TDCC.", "snippet_links": [{"key": "infringement-of", "type": "clause", "offset": [32, 47]}, {"key": "third-party-patents", "type": "definition", "offset": [52, 71]}, {"key": "the-development", "type": "clause", "offset": [108, 123]}, {"key": "offer-for-sale", "type": "definition", "offset": [143, 157]}, {"key": "this-agreement", "type": "clause", "offset": [270, 284]}, {"key": "production-technology", "type": "definition", "offset": [356, 377]}, {"key": "owned-by", "type": "definition", "offset": [378, 386]}, {"key": "product-technology", "type": "clause", "offset": [394, 412]}, {"key": "the-parties-shall", "type": "clause", "offset": [460, 477]}, {"key": "meet-to-discuss", "type": "clause", "offset": [487, 502]}, {"key": "action-to-be-taken", "type": "clause", "offset": [517, 535]}, {"key": "infringement-litigation", "type": "definition", "offset": [566, 589]}, {"key": "determine-the", "type": "clause", "offset": [622, 635]}, {"key": "with-regard-to", "type": "clause", "offset": [653, 667]}, {"key": "sole-discretion", "type": "clause", "offset": [704, 719]}, {"key": "reasonably-necessary", "type": "clause", "offset": [809, 829]}, {"key": "in-the-event", "type": "clause", "offset": [885, 897]}, {"key": "a-settlement", "type": "clause", "offset": [912, 924]}, {"key": "the-litigation", "type": "clause", "offset": [928, 942]}, {"key": "license-to", "type": "clause", "offset": [964, 974]}, {"key": "third-party-technology", "type": "definition", "offset": [979, 1001]}, {"key": "payments-in", "type": "clause", "offset": [1053, 1064]}, {"key": "article-6", "type": "definition", "offset": [1065, 1074]}, {"key": "additional-royalties", "type": "definition", "offset": [1094, 1114]}, {"key": "freedom-to-operate", "type": "definition", "offset": [1170, 1188]}, {"key": "the-production", "type": "clause", "offset": [1193, 1207]}], "size": 2, "samples": [{"hash": "lDjSPVlc1w5", "uri": "/contracts/lDjSPVlc1w5#third-party-suit", "label": "Collaboration and License Agreement (Large Scale Biology Corp)", "score": 18.0, "published": true}, {"hash": "eP4O5BmQmr2", "uri": "/contracts/eP4O5BmQmr2#third-party-suit", "label": "Collaboration and License Agreement (Large Scale Biology Corp)", "score": 18.0, "published": true}], "hash": "94dc99527f6c57aeabe516dcdfcdb1be", "id": 8}, {"snippet": "If TDCC and/or a party TDCC has sublicensed are sued for patent infringement of any Third Party patents and said infringement arises out of the development, manufacture, use, offer for sale, sale or importation of TDCC Products, and where such infringement arises solely and directly from the use of Discovery Technology or Production Technology Owned by Biosource licensed hereunder to TDCC, or solely and directly from Product Technology Owned by TDCC under this Agreement, the parties shall promptly meet to discuss the course of action to be taken to resolve or defend any such infringement litigation. In such event, TDCC or the party TDCC sublicensed, as appropriate, shall determine the course of action with regard to such infringement litigation in its sole discretion, and Biosource shall provide TDCC and/or the sublicensee of TDCC with such assistance as is reasonably necessary and shall cooperate in the defense of any such action. In the event that there is a settlement to the litigation, or TDCC or the sublicensee take a license to the Third Party technology, TDCC and Biosource shall re-negotiate the royalties and milestone payments in Article 6 to in light of any additional royalties or costs that TDCC or DAS may have incurred in obtaining freedom to operate for the Discovery Technology Owned and Production Technology by Biosource.", "snippet_links": [{"key": "a-party", "type": "clause", "offset": [15, 22]}, {"key": "infringement-of", "type": "clause", "offset": [64, 79]}, {"key": "third-party-patents", "type": "definition", "offset": [84, 103]}, {"key": "the-development", "type": "clause", "offset": [140, 155]}, {"key": "offer-for-sale", "type": "definition", "offset": [175, 189]}, {"key": "discovery-technology", "type": "definition", "offset": [300, 320]}, {"key": "production-technology", "type": "definition", "offset": [324, 345]}, {"key": "owned-by", "type": "definition", "offset": [346, 354]}, {"key": "product-technology", "type": "clause", "offset": [421, 439]}, {"key": "this-agreement", "type": "clause", "offset": [460, 474]}, {"key": "the-parties-shall", "type": "clause", "offset": [476, 493]}, {"key": "meet-to-discuss", "type": "clause", "offset": [503, 518]}, {"key": "action-to-be-taken", "type": "clause", "offset": [533, 551]}, {"key": "infringement-litigation", "type": "definition", "offset": [582, 605]}, {"key": "the-party", "type": "clause", "offset": [630, 639]}, {"key": "determine-the", "type": "clause", "offset": [680, 693]}, {"key": "with-regard-to", "type": "clause", "offset": [711, 725]}, {"key": "sole-discretion", "type": "clause", "offset": [762, 777]}, {"key": "the-sublicensee", "type": "clause", "offset": [819, 834]}, {"key": "reasonably-necessary", "type": "clause", "offset": [870, 890]}, {"key": "in-the-event", "type": "clause", "offset": [946, 958]}, {"key": "a-settlement", "type": "clause", "offset": [973, 985]}, {"key": "the-litigation", "type": "clause", "offset": [989, 1003]}, {"key": "license-to", "type": "clause", "offset": [1039, 1049]}, {"key": "third-party-technology", "type": "definition", "offset": [1054, 1076]}, {"key": "payments-in", "type": "clause", "offset": [1144, 1155]}, {"key": "article-6", "type": "definition", "offset": [1156, 1165]}, {"key": "additional-royalties", "type": "definition", "offset": [1185, 1205]}, {"key": "freedom-to-operate", "type": "definition", "offset": [1263, 1281]}], "size": 2, "samples": [{"hash": "lDjSPVlc1w5", "uri": "/contracts/lDjSPVlc1w5#third-party-suit", "label": "Collaboration and License Agreement (Large Scale Biology Corp)", "score": 18.0, "published": true}, {"hash": "eP4O5BmQmr2", "uri": "/contracts/eP4O5BmQmr2#third-party-suit", "label": "Collaboration and License Agreement (Large Scale Biology Corp)", "score": 18.0, "published": true}], "hash": "f0bbdcc00d83fb9616063bf89fb2a01e", "id": 9}, {"snippet": "If a Third Party sues a Party (the \"Sued Party\") alleging that the Sued Party's or the Sued Party's Sublicensees' Research to be conducted under this Agreement, Development of any R&D Candidate, Manufacture of Clinical Supplies or Collaboration Products and/or Commercialization of any Collaboration Product infringes or will infringe said Third Party's patent or misappropriates said Third Party's Know How, then upon the Sued Party's request and in connection with the Sued Party's defense of any such Third Party suit, the other Party shall provide reasonable assistance to the Sued Party for such defense and shall join such suit if deemed a necessary party. The Sued Party shall keep the other Party, if such other Party has not joined in such suit, reasonably informed on a quarterly basis, in person or by telephone, prior to and during the pendency of any such suit. The Sued Party shall not admit the invalidity of any Patent Rights within the CAT Patent Rights, the CAT Collaboration Patent Rights, the ELAN Collaboration Patent Rights, the ELAN Patent Rights and/or the Joint Collaboration Patent Rights, nor settle any such suit, without written consent of the other Party. The Parties shall equally share in the litigation expenses, including settlement costs, royalties paid in settlement of any such suit, and the payment of any damages to the Third Party, other than Third Party License Fees which shall be paid pursuant to Section 5.3.5 or 7.1.10(d), as applicable.", "snippet_links": [{"key": "a-third-party", "type": "clause", "offset": [3, 16]}, {"key": "a-party", "type": "clause", "offset": [22, 29]}, {"key": "sued-party", "type": "definition", "offset": [36, 46]}, {"key": "this-agreement", "type": "clause", "offset": [145, 159]}, {"key": "development-of", "type": "clause", "offset": [161, 175]}, {"key": "rd-candidate", "type": "definition", "offset": [180, 193]}, {"key": "clinical-supplies", "type": "definition", "offset": [210, 227]}, {"key": "collaboration-products", "type": "definition", "offset": [231, 253]}, {"key": "in-connection-with", "type": "clause", "offset": [448, 466]}, {"key": "other-party", "type": "definition", "offset": [526, 537]}, {"key": "assistance-to-the", "type": "clause", "offset": [563, 580]}, {"key": "necessary-party", "type": "definition", "offset": [646, 661]}, {"key": "on-a-quarterly-basis", "type": "definition", "offset": [775, 795]}, {"key": "in-person", "type": "clause", "offset": [797, 806]}, {"key": "by-telephone", "type": "definition", "offset": [810, 822]}, {"key": "prior-to", "type": "definition", "offset": [824, 832]}, {"key": "cat-patent-rights", "type": "definition", "offset": [953, 970]}, {"key": "elan-patent-rights", "type": "definition", "offset": [1051, 1069]}, {"key": "joint-collaboration-patent-rights", "type": "definition", "offset": [1081, 1114]}, {"key": "consent-of-the", "type": "clause", "offset": [1158, 1172]}, {"key": "the-parties-shall", "type": "clause", "offset": [1186, 1203]}, {"key": "litigation-expenses", "type": "definition", "offset": [1225, 1244]}, {"key": "settlement-costs", "type": "definition", "offset": [1256, 1272]}, {"key": "settlement-of", "type": "clause", "offset": [1292, 1305]}, {"key": "payment-of", "type": "definition", "offset": [1329, 1339]}, {"key": "the-third-party", "type": "definition", "offset": [1355, 1370]}, {"key": "third-party-license-fees", "type": "definition", "offset": [1383, 1407]}, {"key": "pursuant-to-section", "type": "definition", "offset": [1428, 1447]}], "size": 2, "samples": [{"hash": "hrkDiKEgGl9", "uri": "/contracts/hrkDiKEgGl9#third-party-suit", "label": "Research, Development and Commercialization Agreement (Cambridge Antibody Technology Group PLC)", "score": 18.0, "published": true}], "hash": "06e39861b2468792bd54c77bf53a6ff9", "id": 10}], "next_curs": "ClkSU2oVc35sYXdpbnNpZGVyY29udHJhY3RzcjULEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2Ihl0aGlyZC1wYXJ0eS1zdWl0IzAwMDAwMDBhDKIBAmVuGAAgAA==", "clause": {"children": [], "title": "Third Party Suit", "parents": [["intellectual-property", "Intellectual Property"], ["third-party-claims", "Third Party Claims"], ["miscellaneous", "Miscellaneous"], ["interest", "Interest"], ["nestl\u00e9-health-science-s", "Nestl\u00e9 Health Science S"]], "size": 48, "id": "third-party-suit", "related": [["third-party-proceedings", "Third Party Proceedings", "Third Party Proceedings"], ["legal-action", "Legal Action", "Legal Action"], ["third-party-litigation", "Third Party Litigation", "Third Party Litigation"], ["third-party-ip", "Third Party IP", "Third Party IP"], ["defense-of-the-underlying-proceeding", "Defense of the Underlying Proceeding", "Defense of the Underlying Proceeding"]], "related_snippets": [], "updated": "2025-07-07T12:35:11+00:00", "also_ask": [], "drafting_tip": null, "explanation": "The Third Party Suit clause defines how claims or lawsuits brought by external parties against one of the contracting parties are handled under the agreement. Typically, this clause outlines the procedures for notifying the other party of such claims, the responsibilities for defending against the suit, and the allocation of costs or liabilities that may arise. For example, if a customer sues a service provider due to an issue related to the contract, this clause would specify who manages the defense and who bears the financial consequences. Its core function is to clarify the parties' obligations and protect them from unexpected liabilities arising from third-party actions."}, "json": true, "cursor": ""}}